Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Postmarketing Surveillance Will Report To Deputy Galson Under CDER Reorg.

Executive Summary

FDA's Office of Postmarketing Drug Risk Assessment will be transferred out of the Office of Review Management to report directly to CDER Deputy Steven Galson, MD, under a reorganization proposal.
Advertisement

Related Content

IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV
FDA Sees Risk Management Role For Sales Forces; Drug Safety Cmte. Coming
CDER Deputy Director Galson To Head Drug Center For Several Months
FDA Pediatrics Office Under Murphy Plans To Recruit Review Div. Liaisons
FDA Rx Risk Advisor Seligman Joins From DoE, Reports To CDER's Galson
IMS Risk Management Tool Targets "High Risk" MDs: CERTs Conference
FDA Standardized NDA Review Format Includes Gender Analysis
CDER Deputy Galson Brings Risk Management Experience To FDA Surveillance
CDER Deputy Galson Brings Risk Management Experience To FDA Surveillance
Priority Review Criteria Reassessment Called For In FDA Rezulin Report
Advertisement
UsernamePublicRestriction

Register

PS037882

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel